Press Releases Sandoz Group AG

Equities

SDZ

CH1243598427

Market Closed - Swiss Exchange Other stock markets 11:30:41 2024-05-31 am EDT			5-day change	1st Jan Change
32.06 ^CHF	+1.04%		+0.12%	+18.48%

May. 22	Sandoz: Marketing authorization for Wyost and Jubbonti in the EU	CF
May. 22	Sandoz Group Receives EU Approval for Cancer, Osteoporosis Biosimilars	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fresenius Kabi Announces FDA Acceptance Of ABLA For Prolia® / Xgeva® (Denosumab) Biosimilar Candidate FKS518	May. 31	AQ
Sandoz receives European Commission approval for Wyost and Jubbonti, the first and only biosimilars of denosumab in Europe	May. 23	AQ
European Commission grants first-of-a-kind biosimilar approval	May. 22	AQ
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe	May. 22	GL
Sandoz reports first quarter 2024 sales	May. 07	GL
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG	Apr. 30	GL
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars	Apr. 30	GL
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering	Apr. 22	GL
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines	Mar. 21	GL
Sandoz reports fourth quarter 2023 sales and full-year 2023 results	Mar. 13	GL
Sandoz reports fourth quarter 2023 sales and full-year 2023 results	Mar. 13	AQ
Sandoz receives FDA approval for first and only denosumab biosimilars	Mar. 05	GL
Sandoz announces nominations to the Board of Directors and leadership change	Mar. 05	GL
Sandoz announces nominations to the Board of Directors and leadership change	Mar. 05	AQ
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market	Mar. 04	GL
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market	Mar. 04	AQ
Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs	Feb. 29	GL
Sandoz announces changes in the Board of Directors	Feb. 01	GL
Sandoz announces changes in the Board of Directors	Feb. 01	AQ
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany	Jan. 31	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

SANDOZ : Sandoz’s improvements are worth betting on

May 08, 2024 at 08:08 am EDT